$4.93+0.13 (+2.71%)
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Nuvation Bio Inc. in the Healthcare sector is trading at $4.92. Wall Street consensus targets $12.33 (9 analysts), implying a +150.4% move over the next 12 months. The stock is currently 49% below its 52-week high of $9.75, remaining 6.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ n...
Nuvation Bio (NYSE:NUVB) has completed a technology transfer partnership with Thermo Fisher Scientific for manufacturing IBTROZI. The company announced that the FDA has accepted a supplemental New Drug Application for IBTROZI, supported by new long term data. Updated IBTROZI clinical results in advanced ROS1 positive NSCLC were recently presented at the AACR Annual Meeting. Nuvation Bio comes into these IBTROZI updates with a share price of $4.32 and a mixed return profile. The stock is...
Thermo Fisher Scientific (NYSE:TMO) has completed technology transfer and product introduction for Ibtrozi, a treatment for ROS1-positive non-small cell lung cancer. This marks a key milestone in its collaboration with Nuvation Bio and reflects a deeper role in biopharma manufacturing and oncology drug commercialization. For investors watching NYSE:TMO, this update highlights the company’s position as a partner for complex drug production in cancer care, not just a supplier of equipment and...
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.